BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 34209038)

  • 1. The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape.
    Choi MR; Sosman JA; Zhang B
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.
    Lu B; Yang M; Wang Q
    J Mol Med (Berl); 2016 May; 94(5):535-43. PubMed ID: 26922618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of IL-33/ST2 signaling in the tumor microenvironment and Treg immunotherapy.
    Lei S; Jin J; Zhao X; Zhou L; Qi G; Yang J
    Exp Biol Med (Maywood); 2022 Oct; 247(20):1810-1818. PubMed ID: 35733343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-33/ST2 as a potential target for tumor immunotherapy.
    Jiang W; Lian J; Yue Y; Zhang Y
    Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions.
    Guo H; Bossila EA; Ma X; Zhao C; Zhao Y
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases.
    Chen WY; Tsai TH; Yang JL; Li LC
    Cell Physiol Biochem; 2018; 49(1):349-358. PubMed ID: 30138941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orchestration of immune response by innate lymphoid cell subtype 2 at various tumor microenvironment, a suitable target for cancer immunotherapy.
    Roy R; Das T; Biswas N
    Int Rev Immunol; 2024; 43(2):74-82. PubMed ID: 37599626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-33/ST2 axis in inflammation and immunopathology.
    Milovanovic M; Volarevic V; Radosavljevic G; Jovanovic I; Pejnovic N; Arsenijevic N; Lukic ML
    Immunol Res; 2012 Apr; 52(1-2):89-99. PubMed ID: 22392053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine.
    Fournié JJ; Poupot M
    Front Immunol; 2018; 9():2506. PubMed ID: 30416507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight.
    Andreone S; Gambardella AR; Mancini J; Loffredo S; Marcella S; La Sorsa V; Varricchi G; Schiavoni G; Mattei F
    Front Immunol; 2020; 11():571593. PubMed ID: 33329534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-33 and the intestine: The good, the bad, and the inflammatory.
    Hodzic Z; Schill EM; Bolock AM; Good M
    Cytokine; 2017 Dec; 100():1-10. PubMed ID: 28687373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.
    Zhang X; Chen W; Zeng P; Xu J; Diao H
    Cancer Manag Res; 2020; 12():7527-7537. PubMed ID: 32904627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family.
    Cayrol C; Girard JP
    Immunol Rev; 2018 Jan; 281(1):154-168. PubMed ID: 29247993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory Mechanisms of IL-33-ST2-Mediated Allergic Inflammation.
    Takatori H; Makita S; Ito T; Matsuki A; Nakajima H
    Front Immunol; 2018; 9():2004. PubMed ID: 30233590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling and functions of interleukin-33 in immune regulation and diseases.
    Yi XM; Lian H; Li S
    Cell Insight; 2022 Aug; 1(4):100042. PubMed ID: 37192860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8
    Chen H; Chen Y; Liu H; Que Y; Zhang X; Zheng F
    Front Immunol; 2018; 9():1179. PubMed ID: 29896199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma.
    Jovanovic I; Radosavljevic G; Mitrovic M; Juranic VL; McKenzie AN; Arsenijevic N; Jonjic S; Lukic ML
    Eur J Immunol; 2011 Jul; 41(7):1902-12. PubMed ID: 21484786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases.
    Rostan O; Arshad MI; Piquet-Pellorce C; Robert-Gangneux F; Gangneux JP; Samson M
    Infect Immun; 2015 May; 83(5):1738-48. PubMed ID: 25712928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-33 in Malignancies: Friends or Foes?
    Shen JX; Liu J; Zhang GJ
    Front Immunol; 2018; 9():3051. PubMed ID: 30619376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.